Depression Clinical Trial
Official title:
Virtual Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers: A Pilot Randomized Controlled Trial
NCT number | NCT04583748 |
Other study ID # | 4860 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2022 |
Est. completion date | April 9, 2022 |
Verified date | April 2022 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vision loss is common among older adults and leads to an increased risk for depression and difficulties in daily tasks, thus requiring dependence on caregivers. This study will assess the feasibility of providing two virtual interventions, Sahaj Samadhi Meditation (SSM) and Health Enhancement Program (HEP), to supplement care of patients with irreversible age-related vision loss (IARVL) and their caregivers, with the goal of enhancing mental health and quality of life.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 9, 2022 |
Est. primary completion date | April 9, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Patients diagnosed with irreversible age-related vision loss (IARVL) by an experienced ophthalmologist and/or their caregivers. 2. IARVL patients between the age range of 60 to 85 years, while caregivers between the age range of 18 to 85 years. 3. Be able to provide valid informed consent to participate in the research study. 4. Being able to speak as well as understand English without the requirement for interpretation or other communication assistance. 5. Having no significant self-reported or a physician-diagnosed mental health disorder other than depressive and/or anxiety symptoms. 6. Should reach a minimal threshold of depressive and/or anxiety symptoms as confirmed by either a minimum of Centre for Epidemiologic Studies - Depression (CES-D) 20-item scale score of 16 OR a minimum of 8 on the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A). 7. Have sufficient hearing to be able to follow verbal instructions 8. Have the ability to sit independently without physical discomfort for 30 minutes. 9. Willing and able to attend virtual intervention via Cisco WebEx software, the four initial training sessions of SSM or HEP and at least 6 out of 11 weekly follow-up sessions. 10. Willing to dedicate 20 minutes twice per day six days per week to their assigned home practice. Exclusion Criteria: 1. Inability to provide a valid informed consent. 2. Having an underlying major neurocognitive disorder as suggested by a Montreal Cognitive Assessment (MoCA) score < 21. 3. Having significant suicidal ideation as per self-report (CES-D = 3 on item question 14 and/or 15). 4. Having severe depression as confirmed by a CES-D = 24. 5. Participating in other similar studies. 6. Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder). 7. Self-reported substance abuse or dependence within the past 3 months. 8. Having an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months. 9. Having a terminal medical diagnosis with prognosis of less than 12 months. 10. Having any planned changes to mood-altering medications at the time of enrollment for the next 12 weeks. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | The Art of Living Foundation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Potential Participants Approached Per Month | The number of potential participants approached per month will be calculated as a feasibility measure. | 1 year | |
Primary | Number of Participants who are Successfully Screened | The number of participants who are successfully screened will be calculated as a feasibility measure. | 1 year | |
Primary | Proportion of Successfully Screened in Participants who Enroll | The proportion of successfully screened in participants who enroll in the study will be calculated as a feasibility measure. | 1 year | |
Primary | Rate of Retention | The rate of retention of participants in the study will be calculated as a feasibility measure. | 1 year | |
Primary | Rate of Adherence to Study Protocol | At the end of the study any deviations from the protocol will be examined to determine the rate of adherence to the study protocol. This information will be calculated as a feasibility measure. | 1 year | |
Primary | Proportion of Planned Ratings that are Completed | The proportion of completed planned ratings will be calculated as a feasibility measure. | 1 year | |
Primary | Intervention Cost Per Case | The cost per participant of attending the SSM program will be calculated as a feasibility measure. | 1 year | |
Primary | Percentage of Time Trade-Off (TTO) Questionnaires Completed | The percentage of TTO questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Visual Function Index (VF-14) Questionnaires Completed | The percentage of VF-14 questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Center for Epidemiologic Studies - Depression (CES-D) Questionnaires Completed | The percentage of CES-D questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Questionnaires Completed | The percentage of HADS-A questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Pittsburgh Sleep Quality Index (PSQI) Questionnaires Completed | The percentage of PSQI questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Community Integration Questionnaire (CIQ) Questionnaires Completed | The percentage of CIQ questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Connor-Davidson Resilience Scale (CD-RISC) Questionnaires Completed | The percentage of CD-RISC questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Primary | Percentage of Zarit Burden Interview (ZBI) Questionnaires Completed | The percentage of ZBI questionnaires completed by each participant will be examined at the end of the study to assess the completeness of the data as a feasibility measure. | 1 year | |
Secondary | Change in Health-Related Quality of Life Score | Change in Health-Related Quality of Life (HRQOL) score as measured by the Time Trade-Off questionnaire (TTO) over a 12-week follow-up. TTO scores range between 0 and 1, with higher scores indicating a higher quality of life. | Weeks 0 and 12 | |
Secondary | Change in Vision-Related Quality of Life Score | Change in Vision-Related Quality of Life (VRQOL) score as measured by the Visual Function Index questionnaire (VF-14) over a 12-week follow-up. VF-14 scores range from 0 to 100, with higher scores representing a greater VRQOL. | Weeks 0 and 12 | |
Secondary | Change in Depressive Symptoms | Change in depressive symptoms as measured by change in Center for Epidemiologic Studies - Depression (CES-D) scores over a 12-week follow-up. The possible range of CES-D scores is 0 to 60, with the higher scores indicating the presence of more depressive symptomatology. | Weeks 0 and 12 | |
Secondary | Change in Anxiety Symptoms | Change in anxiety symptoms as measured by change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) scores over a 12-week follow-up. Total scores on the HADS-A range from 0 to 21. Higher scores represent higher levels of psychological distress. | Weeks 0 and 12 | |
Secondary | Change in Sleep Quality: Pittsburgh Sleep Quality Index (PSQI) | Change in sleep quality as measured by change in Pittsburgh Sleep Quality Index (PSQI) scores over a 12-week follow-up. PSQI scores range from 0 to 21. Higher PSQI scores indicate worse sleep quality. | Weeks 0 and 12 | |
Secondary | Change in Community Integration | Change in community integration as measured by change in Community Integration Questionnaire (CIQ) scores over a 12-week follow-up. The overall score for the CIQ ranges from 0 to 29. Higher CIQ score represents greater integration. | Weeks 0 and 12 | |
Secondary | Change in Resilience | Change in resilience as measured by change in Connor-Davidson Resilience Scale (CD-RISC) scores over a 12-week follow-up. Total scores for the CD-RISC range from 0 to 40, with higher scores representing greater resilience. | Weeks 0 and 12 | |
Secondary | Change in Caregiver Burden | Change in caregiver burden as measured by change in Zarit Burden Interview (ZBI) scores over a 12-week follow-up. Total scores for the ZBI range from 0 to 88. Higher scores represent a more severe self-perceived burden of caregiving. | Weeks 0 and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |